Clinical Trial Update: A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites [Phase 3]

View source ↗

Summary

Phase III trial evaluating the efficacy and safety of STALORAL 300 IR Sublingual Immunotherapy in asthmatic patients allergic to house-dust mites has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• House Dust Mite Allergy

Drugs mentioned

• STALORAL 300 IR Sublingual Immunotherapy

Snippet

Sponsor: Stallergenes Greer | Conditions: Allergy | Phase 3 | Status: COMPLETED